Pluri Inc. Logo

Pluri Inc.

Develops placenta-based cell therapeutics using a proprietary 3D cell-expansion platform.

PLUR | TA

Overview

Corporate Details

ISIN(s):
US72942G2030
LEI:
Country:
Israel
Address:
Park Building No. 5, 3508409 Haifa
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Pluri Inc., formerly Pluristem Therapeutics, is a biotechnology company that researches, develops, and manufactures cell-based products and therapeutics. The company specializes in its proprietary 3D cell-expansion technology platform, which is used to create solutions for commercial use aimed at improving human well-being and sustainability. Pluri develops products from placenta-based cells for applications across the medical and pharmaceutical industries, often in collaboration with research partners and academic institutions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-17 02:42
Director's Dealing
Other Report or Announcement
English 244.9 KB
2025-10-17 02:42
Foreign Filer Report
Other Report or Announcement
English 36.4 KB
2025-10-17 02:40
Remuneration Information
Immediate Report
English 161.6 KB
2025-10-17 02:40
Foreign Filer Report
Immediate Report
English 36.4 KB
2025-10-08 18:02
Regulatory News Service
Pluri Subsidiary Coffeesai and Instituto del Cafe de Chiapas Announce Strategic…
English 146.0 KB
2025-10-08 18:02
Foreign Filer Report
Pluri Subsidiary Coffeesai and Instituto del Cafe de Chiapas Announce Strategic…
English 36.5 KB
2025-09-23 17:54
Director's Dealing
Other Report or Announcement
English 152.3 KB
2025-09-23 17:54
Foreign Filer Report
Other Report or Announcement
English 36.5 KB
2025-09-18 03:08
Registration Form
Other Report or Announcement
English 729.3 KB
2025-09-18 03:08
Foreign Filer Report
Other Report or Announcement
English 36.4 KB
2025-09-18 02:33
Registration Form
Other Report or Announcement
English 315.7 KB
2025-09-18 02:33
Registration Form
Other Report or Announcement
English 36.4 KB
2025-09-18 02:31
Registration Form
Other Report or Announcement
English 317.6 KB
2025-09-18 02:31
Foreign Filer Report
Other Report or Announcement
English 36.4 KB
2025-09-18 01:48
Annual Report
Report of Periodic or Interim Report
English 4.1 MB

Automate Your Workflow. Get a real-time feed of all Pluri Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Pluri Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Pluri Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
SoftOx Solutions AS Logo
Develops non-toxic, AMR-safe antimicrobials for wound care, disinfection & airway infections.
Norway SOFTX
Solasia Pharma K.K. Logo
In-licenses and commercializes oncology treatments and supportive care products in Asia.
Japan 4597
Sopharma AD Logo
Develops, manufactures, and distributes pharmaceuticals and generics in Bulgaria and regional markets.
Bulgaria SFA
Spago Nanomedical AB Logo
Developing nanomedicines for precise cancer diagnosis and targeted radionuclide therapy.
Sweden SPAGO
Spexis AG Logo
Clinical-stage biopharma developing macrocyclic therapeutics for rare diseases and oncology.
Switzerland SPEX
Sprint Bioscience Logo
Develops & out-licenses preclinical oncology drugs for difficult-to-treat cancers.
Sweden SPRINT
STADA Arzneimittel AG Logo
A leading European manufacturer of generics, consumer healthcare, and specialty pharmaceuticals.
Germany SAZ
Stayble Therapeutics AB Logo
Develops an injectable drug for lumbar disc herniation pain as an alternative to surgery.
Sweden STABL
STCUBE Logo
Develops first-in-class immunotherapies targeting BTN1A1 for treatment-resistant cancers.
South Korea 052020
STELLA PHARMA CORPORATION Logo
Develops boron drugs for Boron Neutron Capture Therapy (BNCT), a targeted cancer radiation treatment.
Japan 4888

Talk to a Data Expert

Have a question? We'll get back to you promptly.